Abbott Laboratories Corporation

Icahn School of Medicine at Mount Sinai

Christopher C Marohnic

A Scott Muerhoff

David J Hawksworth

Robert N Ziemann

Bryan C Tieman

Kathy Otis

April Ahlberg

John C Prostko

Anthony Scott Muerhoff

Robin A Gutierrez

Suresh M Desai

George J Dawson

Larry G Birkenmeyer

Andrea Branch

M Felicia Bogdan

Francis Eng

M Felisha Bogdan

Bryan Tieman

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.

Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a 'double shot' of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).

Subject anti-HCV antibody detection assays employing NS3 capture peptides

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.

The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.

HCV core lipid binding domain monoclonal antibodies

The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.

HCV antigen-antibody combination assay and methods and compositions for use therein

The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.

HCV NS3 recombinant antigens and mutants thereof for improved antibody detection

Growing community of inventors

Kenosha, WI, United States of America

Christopher C Marohnic